AUS
NZ
UK
CA
USA
IND
Headlines
- Dimerix and Opthea target breakthrough treatments for rare conditions and retinal diseases respectively.
- Recce Pharmaceuticals sets sights on diabetic foot infections with a focus on Indonesia.
- Imricor and Mesoblast explore cutting-edge approaches in cardiovascular and pain management therapies.
Several ASX-listed companies are making significant strides in their phase III clinical trials, marking a critical juncture before potential regulatory approval. Phase III trials are designed to confirm the safety and effectiveness of groundbreaking treatments, offering hope for new therapies in areas with limited options. Success in these trials can enhance a company's market position, while failure can lead to significant financial setbacks.
Dimerix (ASX:DXB)
Dimerix anticipates a pivotal second interim analysis for its ACTION3 global phase III trial focused on the drug DMX-200 by mid-CY25. Designed to address the rare kidney condition focal segmental glomerulosclerosis (FSGS), DMX-200 has received Orphan Drug Designation in the US and Europe, enhancing its potential for future success.
Opthea (ASX:OPT)
Opthea awaits results for two phase III trials in CY25 regarding its drug candidate sozinibercept (OPT-302), aiming to improve treatment outcomes for wet age-related macular degeneration (wet-AMD). With the potential to disrupt a multi-billion dollar market, OPT-302 could become the first superior treatment for wet-AMD in over a decade.
Recce Pharmaceuticals (ASX:RCE)
Recce is preparing a groundbreaking phase III clinical trial for their synthetic anti-infective RECCE 327. This topical gel targets diabetic foot infections in Indonesia, a country with a substantial diabetes patient demographic. The trial aims to establish RECCE 327 as a leader in global anti-infective therapies.
Imricor Medical Systems (ASX:IMR)
Imricor is advancing its MRI-compatible consumable devices with the launch of its pivotal VISABL-AFL clinical trial. Focused on atrial flutter (AFL), the trial supports US FDA approval, with expectations for market entry in H2 CY25. Concurrently, Imricor is initiating a European trial for ventricular tachycardia, addressing unmet needs in cardiac care.
Mesoblast (ASX:MSB)
After obtaining FDA approval for its childhood graft-versus-host disease treatment, Mesoblast is scaling its phase III study for chronic lower back pain. Expanding across 40 US sites, this study reflects Mesoblast's determination to overcome previous trial shortcomings and achieve pivotal FDA approval in new therapeutic areas.
Paradigm Biopharmaceuticals (ASX:PAR)
Paradigm is set to commence patient enrollment for a phase III trial of its repurposed anti-inflammatory drug Zilosul for knee osteoarthritis in Q1 CY25. Building on positive phase II results, Paradigm aims to demonstrate the drug's efficacy in alleviating pain, potentially revolutionizing treatment for osteoarthritis sufferers.
Conclusion
The ongoing phase III trials among these ASX-listed biotechs underscore their potential to innovate and lead in key therapeutic areas. As these companies approach these trials' critical phases, the outcomes will be watched closely, with successful results potentially positioning them as leaders in their respective markets.
